06/05/2006
Dow Jones News Services
(Copyright © 2006 Dow Jones & Company, Inc.)
DOW JONES NEWSWIRES
Bioenvision Inc. (BIVN) said a Phase II trial showed that its drug Evoltra increased response rates and lengthened survival in elderly, high-risk patients with acute myeloid leukemia.
The New York biomedical company said patients considered unsuitable for intensive treatment who were treated with Evoltra achieved a higher overall complete response rate and a longer median survival than the current standard of care.
Bioenvision said patients in the the non-randomized study, all more than 65 years old, had either intermediate or adverse cytogenetics.
Median survival for patients with adverse cytogenetics treated with Evoltra was six months, while patients treated with the current standard of care have a median survival of one month, the company said.
Bioenvision said the trial results will be the basis of its Marketing Authorization Application in Europe.
Bioenvision shares closed Friday down 4 cents, or 0.7%, at $5.98.
-Sara Leitch; 201-938-5400; AskNewswires@dowjones.com
THE THRILL OF VICTORY ;-) & THE AGONY OF DEFEAT ;-(
